NasdaqGM:KODBiotechs
Will Positive Asian MESI Data and Phase 3 Expansion Reshape Kodiak Sciences' (KOD) Eye-Drug Narrative?
Kodiak Sciences has recently begun presenting new clinical and preclinical data for its bispecific eye therapy KSI-101 at the American Uveitis Society and ARVO 2026 meetings, including results from Phase 1b MESI cohorts in the U.S. and Asia that support continued global Phase 3 development.
A key takeaway is that the Asian MESI cohort achieved visual gains consistent with U.S. APEX study outcomes, reinforcing the company’s multi-target bispecific and ABCD platform approach in inflammatory...